BONUS BIOGROUP LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.8 ILa | -0.59% |
|
+3.07% | +0.60% |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 195M 74.17B |
|---|---|---|---|---|---|
| Net income 2022 | -38M -14.45B | Net income 2023 | -28M -10.65B | EV / Sales 2022 | - |
| Net cash position 2022 | 41.67M 15.85B | Net cash position 2023 | 14.82M 5.63B | EV / Sales 2023 | - |
| P/E ratio 2022 |
-5.79
x | P/E ratio 2023 |
-3.34
x | Employees | 57 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 54.94% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.59% | ||
| 1 week | +3.07% | ||
| Current month | -11.11% | ||
| 1 month | -25.66% | ||
| 3 months | -8.70% | ||
| 6 months | +15.86% | ||
| Current year | +0.60% |
1 week
16.10
17.00
1 month
15.2022.20
Current year
15.2032.00
1 year
14.1032.00
3 years
13.90175.00
5 years
13.90175.00
10 years
13.90175.00
| Managers | Title | Age | Since |
|---|---|---|---|
Shai Meretzki
FOU | Founder | 55 | 12-04-28 |
Yoni Livne
DFI | Director of Finance/CFO | 49 | 14-05-31 |
Atara Novak
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shai Meretzki
FOU | Founder | 55 | 12-04-28 |
Benjamin Shafir
BRD | Director/Board Member | 73 | 20-09-28 |
Gil Shapira
BRD | Director/Board Member | 65 | 12-04-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 16.8 | -0.59% | 249,491 |
| 24-04-24 | 16.9 | +3.68% | 697,418 |
| 24-04-21 | 16.3 | 0.00% | 514,538 |
| 24-04-18 | 16.3 | 0.00% | 1,006,376 |
| 24-04-17 | 16.3 | -1.21% | 1,472,885 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 07:24 am EDT
More quotes
Bonus Biogroup Ltd, formerly Oceana Advanced Industries Ltd, is an Israel-based product-focused biotechnology company applying technology for supplying bone regeneration tissues. The Company is developing cell therapy products based on autologous and allogeneic bone implants that will enable efficient bone transplant and provide cellular-based bone replacement prosthetics for repairing bone lesions. It is targeting a worldwide market for the treatment of major disorders such as bone and cartilage related arthritis, osteoporosis, and various types of bones and joint trauma such as hip fractures and knee injuries, among others. On April 29, 2012, Bonus Bio Group Ltd fully acquired Bonus Therapeutic Ltd.
| 1st Jan change | Capi. | |
|---|---|---|
| +0.60% | 52.2M | |
| -28.79% | 949M | |
| -20.09% | 131M | |
| -16.12% | 61.96M | |
| +7.05% | 60.9M |
- Stock Market
- Equities
- BONS Stock
